Leerink Partnrs Has Positive Outlook of KROS FY2025 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Leerink Partnrs upped their FY2025 EPS estimates for Keros Therapeutics in a note issued to investors on Tuesday, May 6th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of $0.94 per share for the year, up from their previous estimate of $0.87. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. During the same quarter in the previous year, the firm earned ($1.21) EPS.

A number of other analysts also recently issued reports on KROS. Oppenheimer lowered their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a report on Thursday, January 16th. Scotiabank lowered their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research report on Thursday, January 16th. Wells Fargo & Company cut their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Finally, Cantor Fitzgerald cut Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.67.

Keros Therapeutics Stock Up 2.3 %

Shares of NASDAQ KROS opened at $14.02 on Thursday. Keros Therapeutics has a 52 week low of $9.12 and a 52 week high of $72.37. The business’s 50 day moving average price is $12.16 and its 200 day moving average price is $25.02. The firm has a market cap of $569.37 million, a P/E ratio of -2.69 and a beta of 1.32.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the acquisition, the insider now owns 4,392,737 shares of the company’s stock, valued at $44,498,425.81. The trade was a 27.01 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. FNY Investment Advisers LLC bought a new stake in shares of Keros Therapeutics during the 1st quarter valued at about $25,000. CWM LLC lifted its stake in Keros Therapeutics by 10,157.7% during the first quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after purchasing an additional 2,641 shares during the last quarter. AlphaQuest LLC increased its position in shares of Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after acquiring an additional 2,964 shares in the last quarter. Virtus ETF Advisers LLC grew its stake in Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Keros Therapeutics during the 4th quarter valued at $90,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.